NAVA.OL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 1426 min ago

@ NOK34.00

Išleistas: 26 bal. 2024 @ 10:04

Grąža: 0.00%

Ankstesnis signalas: bal. 25 - 17:13

Ankstesnis signalas: Pardavimas

Grąža: -0.29 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 17:12):
Our systems believe the stock currently is overvalued by 1.18% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	4 319.00
Vidutinė apimtis	80 958.00
Rinkos kapitalizacija	592.72M
EPS	NOK0.390 ( 2023-11-01 )
Kita pelno data	( NOK0 ) 2024-05-31
Last Dividend	NOK0.998 ( 2010-04-13 )
Next Dividend	NOK0 ( N/A )
P/E	28.81
ATR14	NOK0.800 (2.35%)

Koreliacija (AI algo v.1.1b): Overvalued: -1.18% NOK33.60 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.72 (moderate negative)

Trumpas: 0.00 (neutral)

Signal:(75) Neutral

Navamedic ASA Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
NORSE.OL	0.895
SMOP.OL	0.871
NTEL.OL	0.871
TOM.OL	0.868
ENDUR.OL	0.839
XXL.OL	0.838
KIT.OL	0.832
SNI.OL	0.826
BORR.OL	0.815
AYFIE.OL	0.813

10 Labiausiai neigiamai susiję koreliacijos
AKBM.OL	-0.895
ODL.OL	-0.895
SCATC.OL	-0.893
SBX.OL	-0.87
OKEA.OL	-0.858
VOLUE.OL	-0.857
PHO.OL	-0.854
FRO.OL	-0.852
TRVX.OL	-0.846
XPLRA.OL	-0.842

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Navamedic ASA Koreliacija - Valiuta/Žaliavos

-0.17
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.32
( neutral )

-0.42
( neutral )

0.28
( neutral )

Navamedic ASA Finansinės ataskaitos

Annual	2023
Pajamos:	NOK512.00M
Bruto pelnas:	NOK199.05M (38.88 %)
EPS:	NOK0

FY	2023
Pajamos:	NOK512.00M
Bruto pelnas:	NOK199.05M (38.88 %)
EPS:	NOK0

FY	2022
Pajamos:	NOK382.14M
Bruto pelnas:	NOK163.52M (42.79 %)
EPS:	NOK1.750

FY	2021
Pajamos:	NOK278.44M
Bruto pelnas:	NOK111.74M (40.13 %)
EPS:	NOK0.00774

Financial Reports:

No articles found.

Navamedic ASA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)	NOK0 (N/A)

Navamedic ASA Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.91 - average (63.94%) | Divividend Growth Potential Score: 1.583 - No dividend growth expected in the near future

Information

First Dividend	NOK0.998	2010-04-13
Last Dividend	NOK0.998	2010-04-13
Next Dividend	NOK0	N/A
Payout Date	2010-04-27
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	NOK0.998	--
Avg. Dividend % Per Year	0.00%	--
Score	1.13	--
Div. Sustainability Score	5.91
Div.Growth Potential Score	1.583
Div. Directional Score	3.75	--

Next Divdend (Est)
(2024-04-27)

NOK0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

1.13

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2010	NOK0.998	17.80%
2011	NOK0	0.00%
2012	NOK0	0.00%
2013	NOK0	0.00%
2014	NOK0	0.00%
2015	NOK0	0.00%
2016	NOK0	0.00%
2017	NOK0	0.00%
2018	NOK0	0.00%
2019	NOK0	0.00%
2020	NOK0	0.00%
2021	NOK0	0.00%
2022	NOK0	0.00%
2023	NOK0	0.00%
2024	NOK0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ALNG.OL	Dividend King	2023-11-27	Quarterly	2	6.60%	7.04
OKEA.OL	Dividend Knight	2023-12-01	Quarterly	3	5.65%	6.86
SALM.OL	Dividend Knight	2023-06-09	Annually	17	2.80%	4.97
BWLPG.OL	Dividend Knight	2023-11-17	Quarterly	11	1.68%	4.46
ELK.OL	Dividend Knight	2023-05-02	Annually	6	6.64%	4.31
BWO.OL	Dividend Knight	2023-11-20	Quarterly	14	0.87%	3.96
ATEA.OL	Dividend Knight	2023-11-20	Annually	16	2.97%	3.45
HAFNI.OL	Dividend Knight	2023-11-23	Semi-Annually	5	1.18%	3.31
AKER.OL	Dividend Knight	2023-11-07	Semi-Annually	20	2.99%	3.13
AUSS.OL	Dividend Knight	2023-05-26	Annually	17	3.23%	2.93

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00752	1.500	9.85	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00735	1.200	9.76	10.00	[0 - 0.3]
returnOnEquityTTM	0.0175	1.500	-0.916	-1.374	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.111	0.800	9.44	7.56	[1 - 3]
quickRatioTTM	0.469	0.800	-1.948	-1.558	[0.8 - 2.5]
cashRatioTTM	0.201	1.500	9.99	10.00	[0.2 - 2]
debtRatioTTM	0.287	-1.500	5.22	-7.83	[0 - 0.6]
interestCoverageTTM	2.30	1.000	-0.260	-0.260	[3 - 30]
operatingCashFlowPerShareTTM	-0.0520	2.00	-0.0173	-0.0346	[0 - 30]
freeCashFlowPerShareTTM	-0.180	2.00	-0.0898	-0.180	[0 - 20]
debtEquityRatioTTM	0.675	-1.500	7.30	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.378	1.000	7.03	7.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.0404	1.000	-1.192	-1.192	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00595	1.000	-1.144	-1.144	[0.2 - 2]
assetTurnoverTTM	0.977	0.800	6.82	5.46	[0.5 - 2]
Total Score				5.91

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	152.51	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0175	2.50	-0.589	-1.374	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.180	2.00	-0.0598	-0.180	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0520	2.00	-0.0173	-0.0346	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.47	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00175	1.000	-2.54	0	[0.1 - 0.5]
Total Score				1.583

Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.